Novo Holdings backs European fund; Alnylam sends second obesity drug into clinicnews2026-06-04T14:48:51+00:00June 4th, 2026|Endpoints News|
Male contraception startup closes $92.5M Series B; Novartis bets on actiniumnews2026-06-02T14:43:48+00:00June 2nd, 2026|Endpoints News|
Agios licenses Oscotec drug; CEPI funds three potential Ebola vaccinesnews2026-06-01T14:39:37+00:00June 1st, 2026|Endpoints News|
AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansionsnews2026-05-29T15:30:30+00:00May 29th, 2026|Endpoints News|
ICON audit finds overstated revenue; Secretome and Psilera raise cashnews2026-05-28T14:51:09+00:00May 28th, 2026|Endpoints News|
AstraZeneca’s breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wavenews2026-05-27T15:33:06+00:00May 27th, 2026|Endpoints News|
Cartesian secures funding to ‘accelerate’ launch; Editas sells $125M in stocknews2026-05-26T15:06:30+00:00May 26th, 2026|Endpoints News|
Tender offer for Recordati; Sobi’s gout drug passes Phase 3 testnews2026-05-22T15:14:09+00:00May 22nd, 2026|Endpoints News|
Pfizer’s next-gen pneumonia shot beats Prevnar 20; Relay targets $175Mnews2026-05-20T15:04:35+00:00May 20th, 2026|Endpoints News|
Full-Life Technologies raises $150M; Quince’s reboot with pulmonary drugnews2026-05-19T14:38:23+00:00May 19th, 2026|Endpoints News|
